GSK says efficacy of its shingles vaccine remains high after years

British drugmaker GSK (GSK.L) said on Wednesday long-term data showed that its blockbuster shingles vaccine, Shingrix, had 79.7% efficacy in participants aged 50 years and above, six to 11 years after vaccination.